Albumin Based Half-Life Extension Service
For Research Use Only. Not for Clinical Use.
Albumin Based Half-Life Extension is a mature and stable method applied in many approved drugs. Creative Biolabs is a leading service provider that focuses on therapeutic protein development. With years of experience in this area, we can provide suitable half-life extension services to support your protein drugs development.
Introduction of Half-Life Extension Service by Bioactive Natural Protein Conjugation
Albumin is the most abundant protein in the serum with a half-life of about several weeks in vivo. Albumin bears the molecular weight of about 67 kDa above the renal threshold which reduces the renal clearance. Moreover, albumin-specific metabolism involved in Fc receptor (FcRn) dependent recycling also prolongs its half-life.
Due to the main function of albumin is that of a transport protein, such as fatty acids and ions, it is ideally suited as a half-life extension module. Biotherapeutics can be combined with albumin either through non-covalent binding or through genetic fusion. In the past decades, albumin has become a versatile carrier for therapeutic peptides and proteins and diagnostic agents. A peptide or protein with a short half-life can have its half-life significantly prolonged by genetic fusion to the N- or C-terminal of albumin, or by chemical conjugation to a free cysteine residue, employing the FcRn-mediated recycling system.
Fig. 1 Structure of albumin and albumin-based drug delivery strategies. (a) Genetic fusion; (b) Non-covalent binding; (c) Covalent attachment. (Larsen, 2016)
Application of Albumin Based Half-Life Extension Service
The application of the albumin has been extensively studied and various molecules have been joined to albumin to improve their pharmacokinetic profile. Back to 2005, an insulin derivative was created by albumin based half-life extension method and approved immediately, which was developed by attaching insulin molecule to a fatty acid. This product achieved a great commercial success and generate the passion of extending therapeutic proteins half-life research. Over the next decade, with dozens of therapeutic albumin binding proteins have been approved, albumin fusion tends to be one of the most popular methods to achieve half-life extension broad application prospect
Custom Services of Albumin Based Half-Life Extension
Albumin binding to peptides can be facilitated in more than one way and with the help of different classes of helper molecules. Creative Biolabs provides a variety of albumin-based half-life extension strategies to push your drug through approval.
- Non-Covalent Binding of Therapeutic Molecules to Albumin
- Covalent Attachment of Therapeutic Molecules to Albumin
- Genetic Fusion Therapeutic Molecules to Albumin
- Next Generation Albumin Based Half-Life Extension Strategies
Albumin can reversibly bind to many modified recombined proteins. Non-covalent association with albumin allows for a dissociation of the therapeutic protein from albumin, which can improve biosafety and utilization.
Therapeutic compounds have also been generated by the covalent attachment of therapeutic molecules to albumin by a chemical link. This conjunction method is suitable for most drugs including small molecules.
Therapeutic proteins have been genetically fused to albumin to produce biologically active molecules with long half-lives. By this convenient way, purified therapeutic proteins can be produced inside the organism or cell line.
The core means of next generation albumin-based half-life extension is modulation of albumin affinity to FcRn to enhance albumin-based therapeutics. Key to this is the manipulation of the albumin/FcRn interaction by producing albumin variants.
Albumin-based half-life extension has great clinical value and varieties of realization approaches. We will be honored to provide one-stop shop albumin-based half-life extension services to clients. Please don't hesitate to contact us for more details.
Reference
- Larsen, M. T.; et al. Albumin-based drug delivery: harnessing nature to cure disease. Molecular and Cellular Therapies. 2016, 4(1), 3.
Related Services:
- Half-Life Extension Services by Non-Covalent Binding of Therapeutic Molecules to Albumin
- Half-Life Extension Services by Covalent Attachment of Therapeutic Molecules to Albumin
- Half-Life Extension Services by Genetic Fusion Therapeutic Molecules to Albumin
- Next Generation Albumin Based Half-Life Extension Strategies
Please submit a detailed description of your project. Our industry-leading scientists will review the information provided as soon as possible. You can also send emails directly to for inquiries.
For Research Use Only. Not for Clinical Use.